在慢性病中使用双酸盐与心血管死亡有关
Clinical nephrology
|November 15, 2024
概括
在慢性病 (CKD) 患者中,双酸盐的使用显示出心血管疾病 (CVD) 风险增加和心血管疾病死亡风险增加的趋势,与最初的假设相反. 这项研究强调了在CKD群体中与双酸盐相关的潜在风险.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性病 (CKD) 显著增加心血管疾病 (CVD) 的风险,可能是通过血管化.
- 已知双酸盐可以抑制血管化,这表明在降低心血管疾病风险方面具有潜在的益处.
研究的目的:
- 调查双酸盐使用与发生心血管疾病的风险,心血管疾病相关死亡率和患有和没有CKD的个体的全因死亡率之间的关联.
- 测试假设,在CKD患者中使用双酸盐将降低心血管和全因死亡率.
主要方法:
- 这是一项2593名来自Framingham Offspring队列的参与者的纵向观测研究.
- 经倾向评分调整的考克斯回归模型被用于分析双酸盐使用与不良结果之间的关联.
- 参与者根据CKD状态进行了分层 (估计的淋巴球过率<60mL/min/1.73m2).
主要成果:
- 在CKD患者中,双酸盐使用与发生心血管疾病风险增加 (调整HR 1.66) 和心血管死亡风险显著增加 (调整HR 2.20) 的趋势有关.
- 在CKD患者中,双酸盐使用与全因死亡率之间没有发现显著的关联.
- 在非CKD个体中,双酸盐使用与所有原因死亡率的增加有关 (调整后HR为1.59),但没有发生心血管疾病或心血管疾病相关死亡.
结论:
- 与最初的假设相反,在CKD患者中使用双酸盐与心血管疾病事件的增加趋势和心血管疾病死亡率的风险翻倍有关.
- 双酸盐的使用也与没有CKD的个体的全因死亡率增加有关.
- 这些发现表明,在CKD患者中使用双酸盐可能存在风险,需要进一步调查.
相关概念视频
Role of Vitamins in Maintaining Bone Health
3.2K
The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
3.2K
Bone Remodeling
38.2K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
38.2K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
129
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
129
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
391
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391
Renal Failure: Dose Adjustments
67
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
67
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
3
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
3


